LQOF - Laboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, Universidade do Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal.
i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen 208, Porto, 4200-135, Portugal.
Curr Top Med Chem. 2023;23(13):1171-1195. doi: 10.2174/1568026623666230130150029.
Drug repurposing is a strategy used to develop new treatments based on approved or investigational drugs outside the scope of their original clinical indication. Since this approach benefits from the original toxicity data of the repurposed drugs, the drug-repurposing strategy is timesaving, and inexpensive. It has a higher success rate compared to traditional drug discovery. Several repurposing candidates have been identified in silico screening and in vitro methodologies. One of the best examples is non-steroidal anti-inflammatory drugs (NSAIDs). Tumor-promoting inflammation is one of the hallmarks of cancer, revealing a connection between inflammatory processes and tumor progression and development. This explains why using NSAIDs in the context of neoplasia has become a topic of interest. Indeed, identifying NSAIDs with antitumor activity has become a promising strategy for finding novel cancer treatment opportunities. Indeed, several commercial anti-inflammatory drugs, including aspirin, ibuprofen, diclofenac, celecoxib, tepoxalin and cyclovalone, naproxen, and indomethacin have presented antitumor activity, and some of them are already in clinical trials for cancer treatment. However, the benefits and complications of using NSAIDs for cancer treatment must be carefully evaluated, particularly for cancer patients with no further therapeutic options available. This review article provides insight into the drug repurposing strategy and describes some of the well-known NSAIDs that have been investigated as repurposed drugs with potential anticancer activity.
药物重定位是一种将批准或正在研究的药物在其原始临床适应症之外重新用于开发新疗法的策略。由于这种方法受益于重新定位药物的原始毒性数据，因此药物重定位策略省时且廉价。与传统的药物发现相比，它的成功率更高。已经通过计算机筛选和体外方法鉴定了几种重新定位候选药物。最好的例子之一是非甾体抗炎药（NSAIDs）。促进肿瘤的炎症是癌症的标志之一，揭示了炎症过程与肿瘤的进展和发展之间的联系。这解释了为什么在肿瘤发生的情况下使用 NSAIDs 成为一个感兴趣的话题。事实上，确定具有抗肿瘤活性的 NSAIDs 已成为寻找新的癌症治疗机会的有前途的策略。事实上，几种商业抗炎药，包括阿司匹林、布洛芬、双氯芬酸、塞来昔布、替泊沙林和环戊酮、萘普生和吲哚美辛都具有抗肿瘤活性，其中一些已在临床试验中用于癌症治疗。然而，必须仔细评估使用 NSAIDs 治疗癌症的益处和并发症，特别是对于没有其他治疗选择的癌症患者。本文综述了药物重定位策略，并描述了一些已被研究为具有潜在抗癌活性的重新定位药物的知名 NSAIDs。
